MedTrace Logo

Determination of Remifentanil's ED50 for Rapid Sequence Intubation Avoiding Bradycardia and Hypotension in Adults

NCT03065309 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-09-13

No results posted yet for this study

Summary

This study will find the median effective dose of remifentanil for rapid sequence intubation which avoids bradycardia and hypotension

Conditions

Interventions

DRUG

Remifentanil

bolus dose

Sponsors & Collaborators

  • Brasilia University Hospital

    lead OTHER

Principal Investigators

  • Gabriel MN Guimarães, MSc · Head of Anesthesiology

Study Design

Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-25
Primary Completion
2017-02-28
Completion
2017-03-01

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03065309 on ClinicalTrials.gov